ISSN: 1876-1038 (Online)
ISSN: 1574-8871 (Print)

Volume 9, 4 Issues, 2014

Download PDF Flyer

Reviews on Recent Clinical Trials

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Stanislaw R. Burzynski
Burzynski Clinic
9432 Katy Freeway, Ste. 200
Houston, TX 77055

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Cetuximab/Irinotecan-Chemotherapy in KRAS Wild-type Pretreated Metastatic Colorectal Cancer: A Pooled Analysis and Review of Literature.

Author(s): Sandro Barni, Mara Ghilardi, Karen Borgonovo, Mary Cabiddu, Alberto Zaniboni and Fausto Petrelli

Affiliation: Medical Oncology Unit, Oncology Department, Azienda Ospedaliera Treviglio-Caravaggio, Piazzale Ospedale 1, 24047 Treviglio (BG), Italia.


Introduction: Cetuximab and irinotecan are effective agents in advanced colorectal cancer (CRC) after either irinotecanor oxaliplatin-based first-line chemotherapy. Here, the efficacy of this combination in patients with the KRAS wild-type gene as second- or further-line therapy is reviewed and data are collected in a pooled analysis.

Methods: Studies that enrolled pretreated CRC patients for second-line therapy or beyond were identified using electronic databases (PubMed and EMBASE). A systematic analysis was conducted using Comprehensive Meta Analysis (version 2.2.064) to calculate the event rate of response and the 95% confidence interval. The weighted median overall survival (OS) and progression-free survival (PFS) were also calculated with NCSS 2007 software. We tested for significant heterogeneity using Cochran’s chi-square test and the I2 index.

Results: Twenty-five studies published between 2007 and 2012 were eligible for this analysis, with a total of 1,712 KRAS wild-type patients enrolled. The overall response rate was 31.9% with similar response rates of 28.7% for second-line treatment and 31.1% for third or further lines. The overall weighted median OS and PFS were 12.5 and 6 months with a weighted OS of 11.56 and 12.2 months for second- and further-line CRC settings, respectively.

Conclusion: In metastatic KRAS wild-type CRC patients pretreated with one or more lines of therapy, cetuximab plus irinotecan-based chemotherapy is an active treatment. Response rates and survival outcomes appear similar in second-line therapy or beyond.

Keywords: Colorectal cancer, cetuximab, irinotecan, KRAS wild type, second line, pooled analysis.

Purchase Online Rights and Permissions

Article Details

Volume: 8
Issue Number: 2
First Page: 101
Last Page: 109
Page Count: 9
DOI: 10.2174/15748871113089990042

Related Journals

Webmaster Contact: Copyright © 2014 Bentham Science